Psychometric Validation of the Subject Sleep Diary in Patients with Moderate-to-Severe Atopic Dermatitis
- PMID: 40116983
- PMCID: PMC11971097
- DOI: 10.1007/s13555-025-01385-3
Psychometric Validation of the Subject Sleep Diary in Patients with Moderate-to-Severe Atopic Dermatitis
Abstract
Introduction: A subject sleep diary (SSD) capturing 14 sleep parameters was developed to assess daily fluctuations in atopic dermatitis (AD)-associated sleep disturbance. This study aimed to evaluate the psychometric properties of the SSD using data including all randomized patients from the phase 3 ARCADIA 1 (NCT03985943) and ARCADIA 2 (NCT03989349) trials of nemolizumab in adults and adolescents (age ≥ 12 years) with moderate-to-severe AD.
Methods: Reliability, validity, and responsiveness of the SSD were evaluated, and its relationship with the single-item Sleep Disturbance Numerical Rating Scale (SD NRS) was examined using the equipercentile linking method.
Results: In ARCADIA 1 (N = 941), most SSD parameters showed good test-retest reliability (intraclass correlations ≥ 0.70) in patients with stable scores over 1 week on sleep disturbance or itch measures. The SSD parameters of wakefulness after sleep onset (WASO), total awake time (TWT), sleep efficiency (SE), number of times (NWASO-AD) and duration (WASO-AD) of AD-related WASO, and sleep quality/refresh (SQR) showed moderate or strong correlations (r = 0.30-0.66) at baseline, in the expected direction; with the SD NRS and at least one of the measures assessing itch and skin disease-related quality of life (Pruritus Categorical Scale, Peak Pruritus NRS, Average Pruritus NRS, and Dermatology Life Quality Index). Correlations with measures assessing distal concepts were weak for most sleep parameters. Sleep onset latency (SOL), WASO, TWT, SE, NWASO-AD, WASO-AD, and SQR demonstrated good known-groups validity at baseline and week 16, and showed responsiveness based on most anchors used in the analysis. Values of the same percentile rankings for the SD NRS and each SSD parameter were identified. Comparable results were obtained using ARCADIA 2 data (N = 787).
Conclusions: The results provided evidence that the SSD, particularly its SOL, WASO, TWASO, TWT, SE, NWASO-AD, WASO-AD, and SQR parameters, is reliable and valid to measure multidimensional concepts of sleep disturbance in clinical studies.
Clinical trial registration: NCT03985943, NCT03989349.
Keywords: Atopic dermatitis; Patient-reported outcome; Psychometrics; Sleep disturbance.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of Interest: Jonathan I. Silverberg has received grants as a consultant and/or advisory board member for AbbVie, Alamar, Aldena, Amgen, AObiome, Arcutis, Arena, Asana, Aslan, BioMX, Biosion, Bodewell, Boehringer-Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi-Genzyme, Shaperon, Union; speaker for AbbVie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, and Sanofi-Genzyme; institution received grants from Galderma, Incyte, and Pfizer. Danielle N. Rodriguez, Carla Dias-Barbosa, and Dina Filipenko are employees of Evidera, which was paid by Galderma for work relating to this study. Liliana Ulianov, Christophe Piketty, and Jorge Puelles are employees of Galderma, which funded this study. Ethical Approval: The clinical trials that provided data for this study were conducted in accordance with the Helsinki Declaration of 1964 and its later amendments, good clinical practice guidelines, and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines. Both trials were initiated after approval from applicable regulatory authorities and the independent ethics committee or institutional review board at each participating site. All patients or their legal guardians provided written informed consent/assent prior to enrollment.
Figures

Similar articles
-
Content Validity and Psychometric Validation of an Adapted Version of the Subject Sleep Diary in Prurigo Nodularis.Dermatol Ther (Heidelb). 2025 Jun;15(6):1405-1426. doi: 10.1007/s13555-025-01406-1. Epub 2025 Apr 23. Dermatol Ther (Heidelb). 2025. PMID: 40266487 Free PMC article.
-
Capturing patient-reported sleep disturbance in atopic dermatitis clinical trials.J Patient Rep Outcomes. 2024 Jul 15;8(1):73. doi: 10.1186/s41687-024-00751-7. J Patient Rep Outcomes. 2024. PMID: 39008191 Free PMC article. Review.
-
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials.Lancet. 2024 Aug 3;404(10451):445-460. doi: 10.1016/S0140-6736(24)01203-0. Epub 2024 Jul 24. Lancet. 2024. PMID: 39067461 Clinical Trial.
-
Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.Health Qual Life Outcomes. 2021 Oct 23;19(1):247. doi: 10.1186/s12955-021-01877-8. Health Qual Life Outcomes. 2021. PMID: 34688290 Free PMC article.
-
Patient-reported outcome (PRO) instruments for disease severity and quality of life in patients with atopic dermatitis: a systematic review of English and Chinese literature.Ann Transl Med. 2022 Aug;10(16):906. doi: 10.21037/atm-22-3164. Ann Transl Med. 2022. PMID: 36111032 Free PMC article. Review.
References
-
- Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109–22. - PubMed
-
- Bender BG, Ballard R, Canono B, Murphy JR, Leung DY. Disease severity, scratching, and sleep quality in patients with atopic dermatitis. J Am Acad Dermatol. 2008;58(3):415–20. - PubMed
-
- Chang YS, Chiang BL. Sleep disorders and atopic dermatitis: a 2-way street? J Allergy Clin Immunol. 2018;142(4):1033–40. - PubMed
Associated data
LinkOut - more resources
Full Text Sources
Medical
Research Materials